Aptuit has named Manuela Leone as Executive VP, Operations and General Manager of the Aptuit Center for Drug Discovery & Development in Verona, Italy, where the company provides inhaled drug development and clinical supply manufacturing services. Leone was most recently President of Contract Research Services at Harlan Laboratories. Aptuit CEO Jonathan Goldman … [Read more...] about Aptuit names new General Manager of its Verona, Italy development center
News
OrPro announces data from preclinical trial of inhaled thioredoxin
California-based biopharmaceutical company OrPro Therapeutics says that pre-clinical studies of its lead compound, ORP-100, an inhaled thioredoxin, has shown that ORP-100 reduces the viscosity and adhesiveness of the sputum of cystic fibrosis patients both in vitro and in vivo. No inflammation was observed in animals that received "many times the anticipated human … [Read more...] about OrPro announces data from preclinical trial of inhaled thioredoxin
Portugal approves AirFluSal Forspiro
The Portuguese Health Authority (Infarmed) has approved Sandoz's AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to developer Vectura. Sandoz licensed AirFluSal Forspiro from Vectura in 2006. The Portuguese approval covers the 50-250 and 50-500 µg dosage forms. AirFluSal Forspiro is now … [Read more...] about Portugal approves AirFluSal Forspiro
Striverdi Respimat launched in the US
Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said that a savings program will be available, allowing most patients to get the inhaler free for a period of time. The card will provide the … [Read more...] about Striverdi Respimat launched in the US
Formex adds personnel, equipment
California-based CDMO Formex has announced the hires of two new scientists, Ke Shi and Wade Pathak, as well as the acquisition of new spray drying and capsule filling equipment. Formex Senior Director of Business Development Yvonne Verburgt said, "The addition of Dr. Pathak and Dr. Shi to the scientific staff shows Formex's commitment to operate at the cutting … [Read more...] about Formex adds personnel, equipment
Teva to focus on respiratory, CNS drug businesses
Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug development programs currently underway at Teva in other therapeutic areas will be divested or discontinued, with the $150-200 … [Read more...] about Teva to focus on respiratory, CNS drug businesses
Savara raises $10 million for AeroVanc development
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis patients, as well as the closing of a $10 million bridge financing round for further development. In December 2013, AeroVanc received … [Read more...] about Savara raises $10 million for AeroVanc development
Retrophin replaces CEO
Retrophin has announced that Stephen Aselage will take over as interim CEO immediately, replacing company founder and CEO Martin Shkreli. According to reports, Shkreli was fired for "stock trading irregularities" and other rules violations. Aselage commented, "I am excited about the direction and future of Retrophin. We have three marketed products with a growing … [Read more...] about Retrophin replaces CEO
Boehringer Ingelheim plans €170+ million expansion of Respimat production facilities
Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said, it will invest €72 million to expand its Respimat filling operations in Ingelheim. The Boehringer Ingelheim microParts site in Dortmund currently … [Read more...] about Boehringer Ingelheim plans €170+ million expansion of Respimat production facilities
Lightlake gets $1 million investment in two nasal spray products
According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company's naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for the treatment of binge eating disorder for an additional $500,000. In July 2014, the company filed an IND for the opioid reversal indication … [Read more...] about Lightlake gets $1 million investment in two nasal spray products